- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06627569
Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans
August 20, 2026 updated by: VA Office of Research and Development
Exercise Effects on the Neurobiology Underlying Stress-Related Eating Behaviors in Veterans
The purpose of this study is to learn more about how common lifestyle interventions, such as exercise, affect how our brains respond to performing thinking tasks and to viewing pictures of foods and various other objects.
The investigators are also interested in how changes in hormones that might be different in men and women could affect how lifestyle interventions change these brain responses.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to learn more about how common lifestyle interventions, such as exercise, affect how our brains respond to performing thinking tasks and to viewing pictures of foods and various other objects.
The investigators are also interested in how changes in hormones that might be different in men and women could affect how lifestyle interventions change these brain responses.
This will help us to better understand how different lifestyle interventions affect the brain and how this might relate to various behaviors.
Eligible participants will be asked to complete 2 study days before and again after a 12-week intervention period, during which they will either continue with usual activities or be asked to complete exercise sessions four times per week.
They will be randomly assigned to one of these conditions (exercise or not) and will not be able to choose their group assignment.
Study Type
Interventional
Enrollment (Estimated)
132
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kristina T Legget, PhD
- Phone Number: (720) 724-5809
- Email: kristina.legget@va.gov
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045-7211
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contact:
- Kristina T Legget, PhD
- Phone Number: (720) 724-5809
- Email: kristina.legget@va.gov
-
Principal Investigator:
- Kristina T. Legget, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Veteran
- Body mass index (BMI) of 25 or greater
- Physically inactive
- Able to attend study visits in person in Aurora, CO
Exclusion Criteria:
- Currently pregnant
- History of bariatric surgery
- Current eating disorder
- Current treatment with appetite-altering medications (e.g., glucagon-like peptide-1 (GLP-1) agonists)
- Contraindication to MRI (weight > 500 pounds (lbs); claustrophobia; metal or electronic devices in the body)
- Cardiovascular disease, chronic kidney disease, pulmonary disease, or diabetes
- Unable to exercise due to cardiac, pulmonary, neurologic, or orthopedic reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual activity
Participants will keep doing what they usually do for the 12-week intervention period.
They will be asked not to change their usual physical activity levels during this period.
They will meet with study personnel once per week
|
|
|
Experimental: Exercise
Participants will complete 4 aerobic exercise training sessions per week for 12 weeks.
The exercise program will begin at 15 minutes per session and duration will be gradually increased by 5 minutes each week until participants reach 30 minutes per session (with 5 min warm-up and cool-down).
Exercise will be performed at a "moderate" intensity, which will be about 60-70% of your predicted maximal level.
Participants will meet with study personnel once per week.
|
12 weeks of aerobic exercise, with 4 sessions per week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent change in blood oxygen level dependent (BOLD) response to visual food cues as measured by functional magnetic resonance imaging (fMRI)
Time Frame: Baseline, 12 weeks
|
Percent change in blood oxygen level dependent (BOLD) response from baseline to after the 12-week intervention period while viewing visual food cues.
The primary contrast of interest is the comparison of high-calorie food images to nonfood object images.
|
Baseline, 12 weeks
|
|
Change in serum cortisol response to counting task
Time Frame: Baseline, 12 weeks
|
Change from baseline to after the 12-week intervention period in serum cortisol levels (micrograms per deciliter (mcg/dL)) throughout a counting task involving mental math (measured as area under the curve).
|
Baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in heart rate response to counting task
Time Frame: Baseline, 12 weeks
|
Change from baseline to after the 12-week intervention period in heart rate (measured by photoplethysmograph; aggregated in 1 min intervals) throughout a counting task involving mental math (measured as area under the curve).
|
Baseline, 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in percent body fat
Time Frame: Baseline, 12 weeks
|
Change in percent body fat, as measured by dual-energy x-ray absorptiometry, from baseline to after the 12-week intervention period.
|
Baseline, 12 weeks
|
|
Percent change in body weight
Time Frame: Baseline, 12 weeks
|
Percent change in body weight (kilogram (kg)) from baseline to after the 12-week intervention period.
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kristina T. Legget, PhD, Rocky Mountain Regional VA Medical Center, Aurora, CO
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
August 30, 2030
Study Completion (Estimated)
August 30, 2030
Study Registration Dates
First Submitted
October 3, 2024
First Submitted That Met QC Criteria
October 3, 2024
First Posted (Actual)
October 4, 2024
Study Record Updates
Last Update Posted (Actual)
August 24, 2026
Last Update Submitted That Met QC Criteria
August 20, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENDA-009-24S
- I01CX002752 (U.S. NIH Grant/Contract: Department of Veterans Affairs)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
As some journals now require authors to provide access to data, de-identified, anonymized data sets will be created after study results are published, and made available upon request for general research purposes, based on availability of resources.
No proprietary data will be made publicly available.
Sufficient data and descriptors will be made available to confirm conclusions in resulting publications and duplicate statistical analyses.
IPD Sharing Time Frame
Data will become available after publication of study results and be available at least 3 years beyond the completion of the study.
IPD Sharing Access Criteria
Data will be made available upon request for general research purposes, based on availability of resources.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.